Using a new compound to protect the retina from light damage
Formation of Retinyl-Opsins by Retinyl Formate as Molecular Shades Against Light-Induced Retinal Damage
This study is looking at how a special compound called retinyl formate might help protect your eyes from damage caused by bright light, which is especially important for people with Stargardt disease or age-related macular degeneration, and it aims to find new ways to help keep your vision safe.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11012292 on NIH RePORTER |
What this research studies
This research investigates how a compound called retinyl formate can help protect the retina from damage caused by intense light exposure, which is particularly relevant for conditions like Stargardt disease and age-related macular degeneration. The study focuses on how retinyl formate interacts with opsin proteins in the retina, preventing the formation of harmful byproducts that can lead to photoreceptor damage. By exploring this innovative approach, the research aims to develop a new strategy for preserving vision in affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and adolescents with Stargardt disease or those at risk for age-related macular degeneration.
Not a fit: Patients with retinal conditions unrelated to light-induced damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect against vision loss in patients with retinal diseases.
How similar studies have performed: While this approach is innovative, similar research has shown promise in using chromophore analogs to mitigate retinal damage.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Hong, John Dong-Hoon — University of California-Irvine
- Study coordinator: Hong, John Dong-Hoon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.